A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Small Animal Imaging Core Bookmark and Share

Small Animal Imaging Core

The Small Animal Imaging Core (SAIC) is directed by Dr. David Colcher and staffed by Dr. James Bading (Imaging Physicist) and Desiree Crow (Core Manager).
 
Preliminary testing in laboratory animals has long had an essential role in the development of new pharmaceuticals and methods for treating human disease. The current development of sophisticated transgenic animal models as well as a growing recognition of the importance of understanding disease processes in the context of the living host has extended the use of animal experimentation beyond safety and efficacy testing into the realm of mechanistic investigation. Non-invasive imaging makes it possible to perform multiple measurements over time in the same animal, thereby enhancing data quality in studies of dynamic molecular and physiologic processes as well as greatly reducing the number of animals required for such studies.
 
During the last several years, scanners for small animals have become commercially available for all of the established modalities of medical imaging (X-ray, CT, MRI, SPECT, PET, ultrasound), as well as for optical imaging. With this technology, the dynamic biodistribution of therapeutic agents as well as vital processes such as gene expression, cell trafficking, cell viability, cell proliferation, tissue hypoxia and angiogenesis can be monitored non-invasively in the intact animal.
 
Small animal imaging has become indispensable to medical research and development and helps the investigator remain competitive for extramural funding.
 
Services
  • Providing consultation to investigators regarding the design, performance and analysis of animal imaging experiments
 
  • Ensuring proper maintenance and calibration of the equipment assigned to the laboratory
 
  • Operating the equipment assigned to the Laboratory or, where appropriate (e.g. for optical imaging equipment), training investigators or their technicians to operate the equipment
 
  • Handling, administering, surveying, tracking and disposing of radioactive materials used in imaging experiments
 
  • Ensuring that all experiments conducted within the Laboratory are performed according to approved protocols
 
Research reported in this publication included work performed in the Small Animal Imaging Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Equipment

The SAIC currently supports radionuclear, X-ray and fluorescence optical bioluminescence imaging in small animals. Imaging systems in hand include:
 
  • 2 units for optical bioluminescence (IVIS 100, Caliper)
  • 1 unit for fluorescence imaging (IUIS 100, Caliper)
  • 1 gamma camera (g IMAGER; Biospace, Inc.)
  • 1 PET scanner (microPET R4; Siemens)
  • 1 CT scanner (microCAT II Hi-Res; Siemens)
 
The microPET and microCAT are readily used in tandem to generate coregistered functional-anatomic PET/CT images. The Imaging Laboratory is also equipped with a gamma counter (Wallac Wizard 3”; Perkin-Elmer, Inc.).
 
Functional Imaging studies are conducted using a dedicated small animal gamma camera and the microPET system. Engineered antibody constructs (as well as other proteins and peptides) are being labeled with radioiodine (123I/124I) or radiometals (111In/64Cu). Planar imaging studies are being performed using125I- and123I-labeled antibody constructs and/or111In conjugated to the antibody construct using an appropriate chelate linker. The positron emission tomography (PET) studies use124I-labeled antibody constructs as well as64Cu?conjugated to the antibody construct using an appropriate chelate linker (e.g. DOTA), or18F-labeled deoxyglucose or other commercially available compounds labeled with short-lived positron-emitting radioisotopes. Labeled constructs are evaluated in biodistribution and tumor uptake studies in murine xenograft models.
 
Xenogen Biophotonic Imaging Systems
The Xenogen IVIS 100 is a non-invasive, real-time system forin vivoimaging of bioluminescence and fluorescence. In this context, bioluminescence results from enzyme-mediated chemical reactions involving injected substrates. The most commonly used enzyme/substrate combination is luciferase/luciferin. The luciferase gene is incorporated into cells so as to be constitutively (i.e., continuously) expressed for monitoring cellular growth and anatomic location. Alternatively, luciferase may be placed under the control of a promoter of interest and used as a reporter gene. When the animal is injected with luciferin, the luciferase in the cells (e.g. hematopoietic stem cells, tumor, or engineered T-cells) activates the luciferin resulting in the emission of light. Xenogen’s cooled charge-coupled device (CCD) camera system captures the resulting image and allows quantitative analysis of the acquired emissions. These images can be used to monitor cellular activity and track gene expression, the spread of a disease, and the effects of new therapeutics.
   
BiospacegIMAGER
ThegIMAGER is a high-resolution planar scintigraphic camera that combines a customized single 120 mm diameter, 4 mm thick CsI scintillation crystal with a position-sensitive photomultiplier tube to provide to a circular 100 mm diameter field of view. The thickness and composition of the crystal were optimized for use with111In. ThegIMAGER can be used with any of a series of parallel hole collimators designed for the gamma ray emissions of various radioisotopes as well as for various combinations of sensitivity and resolution. We have a collimator designed specifically for imaging mice injected with111In.
   
Small Animal PET Scanner (microPET R4)
The small animal PET scanner (microPET R4) provides fully 3-dimensional PET imaging with spatial resolution of better than 2.0 mm and quantitative accuracy for measurement of tissue activity concentration on the order of 10%. The scanner employs rings of contiguous discrete detectors. The 8 cm axial field of view is adequate for simultaneous whole body imaging of mice. Advanced image reconstruction software is available that provides resolution approaching 1.0 mm. Quantitative accuracy is supported by scatter, dead time and measured attenuation corrections. The system is controlled by a PC running under WINDOWS XT. It includes a fully developed image analysis package that supports volumetric regions of interest and fusion of PET with coregistered anatomic CT or MRI. The microPET system is a powerful instrument for studying thein vivopharmacokinetics, pharmacodynamics and efficacy of novel therapeutic agents.
   
Small-animal CT Scanner (microCAT II Ultra Hi-Res)
The new small-animal CT scanner (microCAT II Ultra Hi-Res) features a continuously tunable source that can provide x-ray peak energies from 20 to 130 kV and spatial resolution ranging from 100 mm down to 15 mm. The scanner is completely self-shielded. Its detector (phosphor screen coupled through a fiber optic light pipe to a CCD chip) is large enough to simultaneously image an entire mouse at low resolution, and the beam can be collimated to prevent exposure of tissues outside the field of interest. The unit is equipped for respiratory gating and has a video camera that enables monitoring of the animal once inside the imaging chamber. The system console is a Windows-based PC. A dedicated image reconstruction engine delivers images in “real-time”, i.e. by the end of scan for image sizes up to 512×512×512 voxels. Images are viewed on a separate, UNIX?based workstation running a powerful suite of image rendering and analysis tools under the AMIRA® package. Of particular importance is the seamless interface between the microCAT and the microPET, which are both from Siemens/CTIMI. The microCAT bed is exchangeable between the two scanners, and the microPET image viewing and analysis package (ASIPro®) supports PET-CT fusion imaging.
 

Pricing

Current service offering and pricing can be found on our iLab site. Please contact us for further questions.

Small Animal Imaging Core

Small Animal Imaging Core

The Small Animal Imaging Core (SAIC) is directed by Dr. David Colcher and staffed by Dr. James Bading (Imaging Physicist) and Desiree Crow (Core Manager).
 
Preliminary testing in laboratory animals has long had an essential role in the development of new pharmaceuticals and methods for treating human disease. The current development of sophisticated transgenic animal models as well as a growing recognition of the importance of understanding disease processes in the context of the living host has extended the use of animal experimentation beyond safety and efficacy testing into the realm of mechanistic investigation. Non-invasive imaging makes it possible to perform multiple measurements over time in the same animal, thereby enhancing data quality in studies of dynamic molecular and physiologic processes as well as greatly reducing the number of animals required for such studies.
 
During the last several years, scanners for small animals have become commercially available for all of the established modalities of medical imaging (X-ray, CT, MRI, SPECT, PET, ultrasound), as well as for optical imaging. With this technology, the dynamic biodistribution of therapeutic agents as well as vital processes such as gene expression, cell trafficking, cell viability, cell proliferation, tissue hypoxia and angiogenesis can be monitored non-invasively in the intact animal.
 
Small animal imaging has become indispensable to medical research and development and helps the investigator remain competitive for extramural funding.
 
Services
  • Providing consultation to investigators regarding the design, performance and analysis of animal imaging experiments
 
  • Ensuring proper maintenance and calibration of the equipment assigned to the laboratory
 
  • Operating the equipment assigned to the Laboratory or, where appropriate (e.g. for optical imaging equipment), training investigators or their technicians to operate the equipment
 
  • Handling, administering, surveying, tracking and disposing of radioactive materials used in imaging experiments
 
  • Ensuring that all experiments conducted within the Laboratory are performed according to approved protocols
 
Research reported in this publication included work performed in the Small Animal Imaging Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Equipment

Equipment

The SAIC currently supports radionuclear, X-ray and fluorescence optical bioluminescence imaging in small animals. Imaging systems in hand include:
 
  • 2 units for optical bioluminescence (IVIS 100, Caliper)
  • 1 unit for fluorescence imaging (IUIS 100, Caliper)
  • 1 gamma camera (g IMAGER; Biospace, Inc.)
  • 1 PET scanner (microPET R4; Siemens)
  • 1 CT scanner (microCAT II Hi-Res; Siemens)
 
The microPET and microCAT are readily used in tandem to generate coregistered functional-anatomic PET/CT images. The Imaging Laboratory is also equipped with a gamma counter (Wallac Wizard 3”; Perkin-Elmer, Inc.).
 
Functional Imaging studies are conducted using a dedicated small animal gamma camera and the microPET system. Engineered antibody constructs (as well as other proteins and peptides) are being labeled with radioiodine (123I/124I) or radiometals (111In/64Cu). Planar imaging studies are being performed using125I- and123I-labeled antibody constructs and/or111In conjugated to the antibody construct using an appropriate chelate linker. The positron emission tomography (PET) studies use124I-labeled antibody constructs as well as64Cu?conjugated to the antibody construct using an appropriate chelate linker (e.g. DOTA), or18F-labeled deoxyglucose or other commercially available compounds labeled with short-lived positron-emitting radioisotopes. Labeled constructs are evaluated in biodistribution and tumor uptake studies in murine xenograft models.
 
Xenogen Biophotonic Imaging Systems
The Xenogen IVIS 100 is a non-invasive, real-time system forin vivoimaging of bioluminescence and fluorescence. In this context, bioluminescence results from enzyme-mediated chemical reactions involving injected substrates. The most commonly used enzyme/substrate combination is luciferase/luciferin. The luciferase gene is incorporated into cells so as to be constitutively (i.e., continuously) expressed for monitoring cellular growth and anatomic location. Alternatively, luciferase may be placed under the control of a promoter of interest and used as a reporter gene. When the animal is injected with luciferin, the luciferase in the cells (e.g. hematopoietic stem cells, tumor, or engineered T-cells) activates the luciferin resulting in the emission of light. Xenogen’s cooled charge-coupled device (CCD) camera system captures the resulting image and allows quantitative analysis of the acquired emissions. These images can be used to monitor cellular activity and track gene expression, the spread of a disease, and the effects of new therapeutics.
   
BiospacegIMAGER
ThegIMAGER is a high-resolution planar scintigraphic camera that combines a customized single 120 mm diameter, 4 mm thick CsI scintillation crystal with a position-sensitive photomultiplier tube to provide to a circular 100 mm diameter field of view. The thickness and composition of the crystal were optimized for use with111In. ThegIMAGER can be used with any of a series of parallel hole collimators designed for the gamma ray emissions of various radioisotopes as well as for various combinations of sensitivity and resolution. We have a collimator designed specifically for imaging mice injected with111In.
   
Small Animal PET Scanner (microPET R4)
The small animal PET scanner (microPET R4) provides fully 3-dimensional PET imaging with spatial resolution of better than 2.0 mm and quantitative accuracy for measurement of tissue activity concentration on the order of 10%. The scanner employs rings of contiguous discrete detectors. The 8 cm axial field of view is adequate for simultaneous whole body imaging of mice. Advanced image reconstruction software is available that provides resolution approaching 1.0 mm. Quantitative accuracy is supported by scatter, dead time and measured attenuation corrections. The system is controlled by a PC running under WINDOWS XT. It includes a fully developed image analysis package that supports volumetric regions of interest and fusion of PET with coregistered anatomic CT or MRI. The microPET system is a powerful instrument for studying thein vivopharmacokinetics, pharmacodynamics and efficacy of novel therapeutic agents.
   
Small-animal CT Scanner (microCAT II Ultra Hi-Res)
The new small-animal CT scanner (microCAT II Ultra Hi-Res) features a continuously tunable source that can provide x-ray peak energies from 20 to 130 kV and spatial resolution ranging from 100 mm down to 15 mm. The scanner is completely self-shielded. Its detector (phosphor screen coupled through a fiber optic light pipe to a CCD chip) is large enough to simultaneously image an entire mouse at low resolution, and the beam can be collimated to prevent exposure of tissues outside the field of interest. The unit is equipped for respiratory gating and has a video camera that enables monitoring of the animal once inside the imaging chamber. The system console is a Windows-based PC. A dedicated image reconstruction engine delivers images in “real-time”, i.e. by the end of scan for image sizes up to 512×512×512 voxels. Images are viewed on a separate, UNIX?based workstation running a powerful suite of image rendering and analysis tools under the AMIRA® package. Of particular importance is the seamless interface between the microCAT and the microPET, which are both from Siemens/CTIMI. The microCAT bed is exchangeable between the two scanners, and the microPET image viewing and analysis package (ASIPro®) supports PET-CT fusion imaging.
 

Pricing

Pricing

Current service offering and pricing can be found on our iLab site. Please contact us for further questions.
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media
 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 


NEWS & UPDATES
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...
  • Jana Portnow, M.D., associate director of the Brain Tumor Program at City of Hope, didn’t expect to specialize in treating brain tumors. But, early in her career, she undertook a year of research on pain management and palliative care and, in that program, got to know many patients with brain tumors. After that...
  • Ask any patient: Nurses are as pivotal in their care as doctors. They answer the call of a patient in the middle of the night, they hold the patient’s hand as he or she takes on yet another round of treatment and, in the best-case scenario, they wave goodbye as the patient leaves the hospital, […]
  • Many oncologists, not to mention their patients, might think that there’s no place for mathematical analysis in the treatment of cancer. They might think that all treatment decisions are based on unique factors affecting individual patients, with no connection to other patients and their treatment regimen...
  • Within three days in 2007, Stephanie Hosford, then 37, learned that she was pregnant with her long-awaited second child – and that she had triple-negative breast cancer. Soon afterward, Hosford discovered that she and her husband, Grant, had been approved to adopt a little girl from China.  After encountering m...